➤Cabozantinib S-malate Crystalline form N2 (Innovator form).
➤Cabozantinib HCI – An alternate salt providing 505(b)(2)
opportunities in the US and early launch opportunities in Europe, Brazil, Turkey, Mexico, South Korea, and many other countries.
➤Particle Size Distribution (PSD) – D (90) < 25 Micron, with customized PSDs available based on customer needs.
➤ Quality by Design (QbD) approach for efficiency and high quality.
➤ Robust impurity control strategy for safety and scalability.
We are excited to present an exceptional opportunity related to our Cabozantinib API, which is available for your formulation needs. As one of the first global manufacturers of generic APIs, we have successfully filed the USDMF for Cabozantinib, ensuring the highest quality and regulatory compliance. We look forward to discussing how our product can support your formulations and contribute to your business success.
